Infectious Disease Deal Benchmarks 2026

Median Upfront

$488M

Range: $281M - $681M

Total Deal Value

$1.9B

Range: $1.3B - $2.5B

Royalty Rate

7.7% - 15.4%

Tiered up to 19.4%

Dev Milestones

$313M

Range: $224M - $405M

Model Your Deal

Market Analysis

Infectious disease licensing in 2026 spans antivirals, novel antibiotics, and next-generation vaccines. Phase 2 small molecule deals in the infectious disease space carry a median total deal value of $1.9B, with upfront payments between $281M and $681M. HIV long-acting regimens, HBV functional cures, and broad-spectrum antivirals represent the highest-value deal categories.

Deal structures in infectious disease are shaped by the unique dynamics of antimicrobial stewardship, pandemic preparedness funding, and government procurement contracts. Development milestones average $313M, with regulatory milestones of $328M often tied to expedited pathways such as QIDP designation. Commercial milestones of $783M reflect both commercial and public-health market opportunities.

Royalty rates for infectious disease deals range from 7.7% to 15.4% at the base tier. Novel antibiotic deals often carry lower base rates but include pull incentive and subscription model-linked commercial milestones. Antiviral deals, particularly in HIV and HBV, support higher royalty structures given the chronic treatment paradigm and large patient populations.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What drives deal activity in antiviral licensing?

Antiviral deal activity is driven by long-acting HIV regimens, HBV functional cure programs, and broad-spectrum antiviral platforms. Phase 2 antiviral deals average $1.9B total deal value. The convergence of gene editing and antiviral strategies (e.g., CRISPR-based HBV cure) is creating a new tier of premium deal opportunities.

How are antibiotic resistance partnerships structured?

Antibiotic resistance partnerships typically feature lower upfront payments but incorporate government-backed pull incentives and subscription-model revenue guarantees. The PASTEUR Act and CARB-X-style funding mechanisms shape deal economics, with total deal values increasingly supported by public-private partnership milestones rather than purely commercial sales projections.

What are typical deal terms for vaccine licensing agreements?

Vaccine licensing deals are characterized by high commercial milestones relative to development milestones, reflecting the large population-based market opportunity. mRNA and self-amplifying RNA vaccine platforms command premium valuations due to manufacturing speed and pandemic preparedness positioning. Adjuvant technology partnerships are a growing deal category.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Infectious Disease Deal Benchmarks 2026

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Rare Disease Deal Overview

Phase 2 Deal Benchmarks

Small Molecule Deals

Gene Therapy Deals

Ready to Calculate Your Deal Terms?